Man Group’s Beta Bionics BBNX Stock Holding History

Man Group’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$419K	Sell	26,770 -12,497	-32%	-$149K	﹤0.01%	2093
2026 Q1	$393K	Buy	39,267 +27,946	+247%	+$413K	﹤0.01%	2140
2025 Q4	$345K	Buy	+11,321	New	+$302K	﹤0.01%	1984

Other funds holding BBNX

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Man Group's BBNX Position: Q2 2026 in Review

Man Group reduced its Beta Bionics (BBNX) stake by 32% in Q2 2026, selling an estimated $149K and leaving 26,770 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

Man Group first reported a position in BBNX in Q4 2025 and has held it in 3 quarters since. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

Man Group held 26,770 shares of Beta Bionics worth $419K as of Q2 2026.
Man Group sold 12,497 Beta Bionics shares in Q2 2026, an estimated $149K.
Beta Bionics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2093 holding.
Man Group first reported a position in Beta Bionics in Q4 2025 and has held it in 3 quarters since.
133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.